Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575794 · ClinicalTrials.gov registry record · Phase 1
Terameprocol in Treating Patients With Recurrent High Grade Glioma
A Phase 1 study of High Grade Glioma (III or IV), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 9
- Study locations
NCT02575794 is a Phase 1 study of High Grade Glioma (III or IV) that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 20 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT02575794, a Phase 1 study of High Grade Glioma (III or IV), has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as terameprocol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- OTHER Pharmacological Study
- DRUG Terameprocol
Study Locations (9)
Pennsylvania
- Abrams Cancer Center of the University of Pennsylvania - Philadelphia
- Hillman Cancer Center at University of Pittsburgh Cancer Institute - Pittsburgh
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
New York
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2023-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575794
The ClinicalTrials.gov registry entry for NCT02575794 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Glioma (III or IV) appearing as the primary indexed condition, and to 2 interventions - of which Pharmacological Study is the first listed.
NCT02575794 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Pennsylvania, Alabama, Maryland.
Frequently Asked Questions
What is clinical trial NCT02575794 about?
NCT02575794 is a clinical study titled "Terameprocol in Treating Patients With Recurrent High Grade Glioma". This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as terameprocol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from div...
What is the current status of trial NCT02575794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-05-03. Estimated completion is 2023-10-04.
What conditions does trial NCT02575794 study?
This clinical trial studies the following conditions: High Grade Glioma (III or IV).
What interventions are being tested in trial NCT02575794?
The interventions under investigation include: Pharmacological Study (OTHER), Terameprocol (DRUG).
Who is sponsoring clinical trial NCT02575794?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02575794 being conducted?
This trial has 9 study locations across Alabama, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.